A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

开始日期2024-11-21

申办/合作机构

UCB Biopharma SRL

NCT04976322

/ Enrolling by invitation临床3期

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

开始日期2021-07-27

申办/合作机构

UCB Biopharma SRL

NCT04571424

/ Completed临床1期

Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Dapirolizumab Pegol (BIIB133) in Healthy Japanese and Caucasian Study Participants

The primary objective of the study is to assess the safety and tolerability of a single intravenous (IV) dose of dapirolizumab pegol (DZP) in Japanese healthy study participants compared with those of Caucasian healthy study participants.
The secondary objectives of the study are to assess the pharmacokinetic(s) (PK) of a single IV dose of DZP in Japanese and Caucasian healthy study participants, to evaluate ethnic sensitivity on the PK of DZP between body weight- and gender-matched Japanese and Caucasian healthy study participants and to evaluate the immunogenicity of a single IV dose of DZP in Japanese and Caucasian healthy study participants.

开始日期2020-10-14

申办/合作机构

Biogen, Inc.

100 项与 Dapirolizumab pegol 相关的临床结果

登录后查看更多信息

100 项与 Dapirolizumab pegol 相关的转化医学

登录后查看更多信息

100 项与 Dapirolizumab pegol 相关的专利（医药）

登录后查看更多信息

489

项与 Dapirolizumab pegol 相关的文献（医药）

2026-03-01·NEUROTOXICOLOGY

Targeting glutamate receptors with IEM-1925: A strategy against soman-induced status epilepticus and neurodegeneration

Article

作者: Wang, Jingyan ; Cao, Manzhu ; Li, Liqin ; Zhang, Yi ; Shi, Jingjing ; Lin, Yuxin ; Jin, Qian ; Chen, Yuanqing

Exposure to organophosphorus nerve agents (OPNAs) like soman frequently develops status epilepticus (SE), leading to brain damage. Existing antiseizure medications (e.g., diazepam, DZP) often demonstrate insufficient efficacy. To develop more effective treatments for OPNA-induced seizures, this study evaluated the efficacy of glutamate receptor antagonists with distinct mechanisms of action in a soman-induced rat seizure model. After 5 min of subcutaneous exposure to 110 μg/kg soman, which induced SE, rats received intraperitoneal injections (10 mg/kg) of perampanel (PER), fanapanel (FNP), IEM-1925 (IEM), or DZP. The results showed that IEM significantly suppressed seizure activity and improved survival. The survival rate of the vehicle-treated control group was 31.25 %, whereas DZP, FNP, and IEM increased survival rates to 50 %, 43.75 %, and 56.25 % respectively. Electroencephalographic (EEG) recordings for 24 h indicated that both DZP and IEM controlled soman-induced SE. However, while DZP initially blocked the onset of seizures, they recurred after its transient anticonvulsant effect wore off. In contrast, IEM reduced behavioral convulsion intensity and total duration of SE. Histopathological examinations (HE, Nissl, immunohistochemistry, and immunofluorescence) showed that IEM attenuated hippocampal CA1, CA2, and DG neuronal damage. Behavioral tests (open field, novel object recognition, and Y maze) confirmed IEM outperformed DZP and the solvent-treated group in ameliorating soman-induced anxiety, cognitive dysfunction, and memory impairment. In conclusion, IEM demonstrates potent triple effects-antiseizure, neuroprotective, and cognitive improving in soman exposure model, providing a novel therapeutic strategy and candidate drug for the medical treatment of OPNAs poisoning.

2026-02-01·EUROPEAN JOURNAL OF IMMUNOLOGY

Curbing Autoimmunity: A New Fab Fragment Targeting CD40‐CD40L Halts B‐Cell Activation and Differentiation

Article

作者: Thiel, Steffen ; Andersen, Ebbe S. ; Valero, Julián ; Troldborg, Anne ; Schinkel, Thea ; Pedersen, Kathrine ; Green, Kenneth ; Kristoffersen, Emil L. ; Rovsing, Anne B. ; Laursen, Nick S. ; Degn, Søren E. ; Palarasah, Yaseelan ; Hansen, Annette G. ; Civit, Laia

ABSTRACT:

Dysregulation of the CD40‐CD40L axis is implicated in autoimmune diseases. Early clinical trials targeting CD40L with antibodies failed due to Fc‐mediated side effects. To address this, we developed an anti‐CD40L Fab fragment, Fab20, designed to block B‐cell activation. Fab20 was evaluated for its binding properties, CD40‐CD40L inhibition, and effects on human B‐cell activation and differentiation using immunoassays, cryo‐electron microscopy, flow cytometry, and cell cultures. Fab20 binds CD40L with a dissociation constant of 70 nM. Structural analysis revealed a “propeller‐like” structure consisting of three Fabs binding to the CD40L trimer, sterically blocking parts of the CD40 binding site. Fab20 effectively inhibited B‐cell activation, maintaining naïve B cells in their inactive state, and suppressed antibody (IgG) production over 14 days. Fab20 represents a promising novel therapeutic approach for treating autoimmune diseases driven by CD40‐CD40L dysregulation. Its mechanism of action, coupled with the absence of Fc‐mediated effects, suggests a favorable safety profile.

2026-02-01·JOURNAL OF FOOD SCIENCE

Modulation of DBS/Zein/Pectin Nanoparticle Properties by Calcium Ions: Physicochemical and Emulsifying Insights

Article

作者: Zhang, Biao ; Jiang, Jinchi ; Cui, Jie ; Zhang, Rongrong ; Li, Wenhui ; Yang, Wenge ; Hu, Yonghong ; Zhang, Jian

ABSTRACT:

This study investigated the effects of Ca 2+ ions on the physicochemical properties of DBS/zein/pectin (DZP) ternary composite nanoparticles by adding varying concentrations of Ca 2+ during particle formation. Ca 2+ ions reduced electrostatic repulsion between colloidal particles, causing collisions and aggregation, which increased particle size. Additionally, Ca 2+ ions decreased α‐helices and increased β‐sheets in the zein molecular chains, weakening interactions between zein and other components, and reducing the thermal stability of the composite particles. At high Ca 2+ concentrations, phase separation occurred, with the crystalline structure nearly disappearing. Ca 2+ ions neutralized surface charges, decreased colloidal particle wettability, and reduced emulsifying capacity. Emulsions prepared with these particles showed that Ca 2+ addition intensified the aggregation of composite particles on the emulsion droplet surface, resulting in pronounced phase separation and reduced emulsion stability. Overall, these results demonstrate that Ca 2+ plays a key regulatory role in governing the structure–property relationships of DZP ternary composite nanoparticles. This study provides mechanistic insight into ion‐mediated regulation of protein–polysaccharide systems and highlights the potential of DZP nanoparticles as calcium‐responsive carriers for food‐related delivery applications.

104

项与 Dapirolizumab pegol 相关的新闻（医药）

2026-03-30

·BioSpace

Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline

iStock, Chee Siong Teh William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunology and inflammation pipeline. Biogen’s litifilimab reduced disease activity in cutaneous lupus erythematosus in a second mid-stage study, providing another derisking step for the company’s immunology and inflammation (I&I) pipeline, according to analysts at RBC Capital Markets. “We believe this should underscore the promise of [Biogen’s] I&I pipeline,” the analysts said in a Sunday note to investors. Litifilimab—also known as liti—met the Phase 2/3 AMETHYST trial’s primary endpoint, showing an 11.8% higher reduction in disease activity in people with cutaneous lupus erythematosus (CLE) as measured by the Cutaneous Lupus Activity Investigators’ Global Assessment Revised (CLA-IGA-R) erythema score of 0-1 (clear/almost clear) at week 16 compared to placebo. Specifically, 14.7% of patients treated with liti achieved this target versus just 2.9% of patients on placebo, Biogen reported at the 2026 American Academy of Dermatology Annual Meeting on Saturday. Treatment with liti was also “associated with rapid and continued improvement in skin disease activity with separation from placebo observed as early as Week 4,” according to Biogen’s press release , with a score of 40.8% vs. 21.0% as measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity-50 (CLASI-50) through week 24. Notably, 16.3%—or 1 in 6—of liti recipients experienced no or minimal disease activity at week 24 compared to none of the placebo recipients. CLE is a serious autoimmune disease that causes skin rashes that can lead to permanent scarring and disfigurement, Diana Gallagher, senior vice president of Biogen’s Multiple Sclerosis and Immunology Disease Unit and Alzheimer’s and Dementia Disease Unit, told BioSpace. Diana Gallagher/ copyright David A. White AMETHYST’s results back an earlier successful Phase 2 trial, dubbed LILAC, in which liti showed a 22%–25% placebo-adjusted advantage at week 16 on the CLASI-50 in patients with CLE, according to RBC. The analysts called the drug’s consistent activity in this metric “encouraging.” Liti’s safety pro consistent with prior studies, Biogen reported. Next up in CLE, a one-year Phase 3 study is expected to produce topline data later next year, according to Gallagher. This trial will allow the company to “fully characterize safety and tolerability, time to effect and durability,” she said, adding that these data will be important to global regulators as well as patients. If approved, liti would be the first targeted therapy for CLE, Biogen said Saturday, and the first “innovative therapy” for the disease in 70 years. A Homegrown Asset Biogen CEO Chris Viehbacher highlighted litifilimab , a humanized IgG1 monoclonal antibody targeting BDCA2, during the company’s fourth quarter 2025 call in February, as an asset due for a lot of data this year. Earnings Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth. February 6, 2026 · 2 min read · Annalee Armstrong Read more Along with CLE, liti is also in two Phase 3 trials for systemic lupus erythematosus (SLE), with data expected in the fourth quarter. Of the two indications, William Blair sees the CLE indication as having the greatest probability of success “given the clinical data to date,” according to a Monday morning note. Liti is a homegrown molecule, Gallagher said, “in a pathway that we spent a lot of time systematically understanding the biology.” The drug targets BDCA2, a protein present in specific cells within the immune system, according to Biogen’s website . The company’s hypothesis is that an antibody against this protein can interrupt the production of interferons, inflammatory molecules that are increased and contribute to disease activity in people with lupus. Biogen’s three therapeutic pillars are neurology, rare disease and immunology, Gallagher told BioSpace in September 2025. In immunology, with its staple multiple sclerosis franchise under increasing pressure from declining sales , Biogen has turned attention to other diseases. This includes lupus, primary membranous nephropathy and immunoglobulin A nephropathy (IgAN), the latter two of which is being targeted with anti-CD38 antibody felzartamab in Phase 3 trials. Another drug, dapirolizumab pegol, is also in Phase 3 trials for SLE, giving Biogen multiple late-stage shots on goal in this indication. “We’re at this inflection point now,” Gallagher told BioSpace in September. “We’ve been working in lupus for almost the whole decade that I’ve been here but really are now at this really exciting point.” Immunology and inflammation Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline With two late-stage programs set to read out in the next 48 months, Biogen is translating its wealth of experience in multiple sclerosis to lupus—developing a pipeline BMO Capital Markets analysts called “thoughtful.” September 9, 2025 · 4 min read · Heather McKenzie Read more Gallagher wouldn’t commit to a timeframe for litifilimab’s commercialization in either CLE or SLE, “but we’re getting much closer,” she said. “I’ve been working on this program for probably over a decade, so to me, it feels like soon.” For RBC, the upcoming SLE readouts “[kick] off a series of potential value-creating catalysts over the next several years, which we believe remain underappreciated and could further the company’s turnaround and generate further share appreciation.” William Blair heralded the CLE readout as a major turning point for Biogen: “With ~415,000 CLE patients across major geographies and breakthrough therapy designation in hand, litifilimab represents an exciting jump into Biogen’s next-generation immunology program, which we expect to bolster its waning multiple sclerosis franchise as it continues to explore new growth opportunities.”

临床结果临床3期临床2期

2026-03-28

·EndPoints

Biogen declares Phase 2 lupus success for anti-BDCA2 antibody

Biogen trumpeted new Phase 2 lupus data on Saturday for a program it hopes will become a pillar of its immunology pipeline. The drug litifilimab improved patients’ skin lesions after 24 weeks, with 14.7% reaching a “clear” or “almost clear” skin score compared to 2.9% of those who took placebo achieving such clearance. The 11.8% difference was statistically significant with a p-value of <0.05, Biogen said. Biogen is banking on continued success from litifilimab as CEO Chris Viehbacher continues his turnaround of the company. As Biogen investors have grown restless with the company’s strategy, Viehbacher and other company executives have pointed toward lupus as a key disease focus — despite not pursuing a CAR-T for lupus like many others. Though CAR-T in lupus and other autoimmune diseases is promising, data remain limited and early. Regardless, several biotechs have seized on the excitement to pivot their CAR-T and CAR-NK programs toward lupus, particularly for patients with severe disease who don’t respond well to current treatments. Saturday’s data come from a trial testing litifilimab in a form of lupus called cutaneous lupus erythematosus, or CLE, which only affects the skin. Biogen is also developing litifilimab for systemic lupus erythematosus (SLE), the most common form of lupus affecting internal organs, according to the Lupus Foundation of America . Another lupus drug being being developed by Biogen, dapirolizumab pegol, has garnered more skepticism, given the lack of a CAR-T program. Viehbacher noted the logistics of CAR-T remain complicated and later-stage data have still yet to read out. Litifilimab is an anti-BDCA2 antibody designed to interfere with lupus patients’ overactive immune systems and tamp down inflammation. Two Phase 3 studies for litifilimab in SLE are expected to read out later this year, per the federal clinicaltrials.gov . A Phase 3 trial in CLE is still ongoing. Last year, Biogen agreed to a $250 million royalty deal with Royalty Pharma on litifilimab.

临床3期临床2期临床结果

2026-03-09

·动脉网

新赛尔宣布与Eledon制药达成战略协作，以推进NCEL-101项目在1型糖尿病中的应用NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation 整合干细胞衍生胰岛与靶向免疫调节的合作ZURICH, Switzerland 苏黎世，瑞士, ，March 9, 2026 2026年3月9日/PRNewswire/ -- NewcelX Ltd. ('NewcelX') (Nasdaq: /PRNewswire/ -- NewcelX Ltd.（“NewcelX”）（纳斯达克：NCEL NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. ('Eledon') (Nasdaq: ），一家致力于推进1型糖尿病干细胞衍生疗法的临床阶段公司，今天宣布与Eledon Pharmaceuticals, Inc.（“Eledon”）（纳斯达克：）达成一项合作研究协议。ELDN ELDN), a clinical-stage immunology company with a focus on transplant medicine. ），一家专注于移植医学的临床阶段免疫学公司。The collaboration is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart (AT-1501), with the goal of supporting durable, immune-protected islet replacement and advancing a potential functional cure for Type 1 Diabetes.. 该合作旨在推进将NewcelX的主导项目NCEL-101与Eledon的在研抗CD40L单克隆抗体特戈鲁巴特（AT-1501）相结合的策略，目标是支持持久的、受免疫保护的胰岛替代，并推动实现1型糖尿病潜在的功能性治愈。Eledon's tegoprubart is a next-generation anti-CD40L monoclonal antibody designed to modulate immune activation pathways central to T-cell–mediated transplant rejection. The collaboration leverages clinical experience from over 100 transplant patients treated with tegoprubart, including patients in kidney, heart and diabetes-related transplant settings, developed under multiple U.S. Eledon的tegoprubart是一种下一代抗CD40L单克隆抗体，旨在调节与T细胞介导的移植排斥反应相关的关键免疫激活途径。该合作利用了来自100多名接受tegoprubart治疗的移植患者的临床经验，包括肾脏、心脏和糖尿病相关的移植环境下的患者，这些研究是在美国多个机构开展的。Food and Drug Administration–cleared Investigational New Drug (IND) applications. This extensive transplant experience provides clinically informed insights and data relevant to cell replacement therapies, and could potentially lead to a clearer regulatory pathway for NCEL-101 while streamlining the development program. 食品和药物管理局批准的试验性新药（IND）申请。这一广泛的移植经验提供了与细胞替代疗法相关的临床信息和数据，可能会为NCEL-101提供更清晰的监管路径，同时简化开发计划。Integrating targeted immune modulation with NCEL-101 is intended to support durable graft survival comparable to outcomes observed with donor human islets (see press . 将靶向免疫调节与NCEL-101相结合，旨在支持持久的移植物存活，其效果可与供体人胰岛观察到的结果相媲美（见新闻发布）。release link 发布链接). ）。Importantly, NCEL-101 remains NewcelX's core therapeutic product, designed to address the shortage of functional insulin-producing cells through scalable, off-the-shelf manufacturing. The immune modulation component is intended to enhance durability and graft survival of the cells. 重要的是，NCEL-101 仍然是 NewcelX 的核心治疗产品，旨在通过可扩展的、现成的制造方式来解决功能性胰岛素生成细胞短缺的问题。免疫调节组件旨在增强细胞的持久性和移植物存活率。Professor Michel Revel, MD, PhD, CSO of NewcelX: 米歇尔·雷维尔教授，医学博士，哲学博士，NewcelX首席科学官：'The collaboration marks an important strategic milestone for NewcelX, enhancing its execution-focused clinical programs and broadening collaboration with established leaders in immune biology and transplant medicine'. “此次合作标志着NewcelX的一个重要战略里程碑，加强了其以执行为重点的临床项目，并拓宽了与免疫生物学和移植医学领域知名领袖的合作。”The collaboration is anticipated to accelerate timelines, establish a well-defined regulatory pathway, and enhance development visibility, supporting NewcelX's strategy to advance its clinical programs efficiently toward pivotal milestones. 预计此次合作将加快进程，建立明确的监管路径，并提高开发的可见性，支持NewcelX高效推进其临床项目迈向关键里程碑的战略。Ronen Twito, Executive Chairman & CEO of NewcelX, added: 纽赛尔公司的执行主席兼首席执行官罗南·特维托补充道：'Collaborating with Eledon Pharmaceuticals represents a meaningful milestone of our product and a strategic step forward for NewcelX. Leveraging Eledon's extensive transplant experience across more than 100 procedures provides us with clinically grounded insight that potentially supports a clearer regulatory pathway and a more efficient development plan for NCEL-101. “与Eledon制药公司合作代表了我们产品的一个重要里程碑，也是NewcelX向前迈出的战略性一步。借助Eledon在100多例移植手术中的丰富经验，我们获得了基于临床的洞察，这可能有助于为NCEL-101提供更清晰的监管路径和更高效的开发计划。”Our focus is to translate this advantage into disciplined execution and long-term shareholder value.'. 我们的重点是将这一优势转化为有纪律的执行和长期的股东价值。About NewcelX 关于NewcelXNewcelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the company's lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. NewcelX 是一家创新的生物制药公司，专注于开发用于治疗 1 型糖尿病的变革性干细胞衍生疗法。公司依托经过验证的人类多能干细胞 (hPSC) 平台，其主导项目 NCEL-101 旨在通过可扩展的、现成的细胞替代方案来恢复功能性胰岛素生产。NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs.. NewcelX 正在推进一种综合性的 1 型糖尿病治疗方案，整合细胞疗法、免疫保护和转化科学，以解决关键的未满足医疗需求。Social Media: 社交媒体：LinkedIn 领英, ，Facebook 脸书, ，X X, ，Instagram InstagramWebsite: 网站：www.newcelx.com www.newcelx.comForward-Looking Statements 前瞻性声明This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example,NewcelX is using forward-looking statements when it discusses how this collaboration is designed to advance combination strategies integrating NCEL-101 with Eledon's investigational anti-CD40L monoclonal antibody, tegoprubart (AT-1501), advancing a potential cure for Type 1 Diabetes, how the collaboration is anticipated to accelerate timelines, establish a well-defined regulatory pathway, and enhance development visibility, NewCelX's strategy to advance its clinical programs efficiently toward pivotal milestones, and creating long-term shareholder value. 本新闻稿包含根据1995年《私人证券诉讼改革法案》及其他适用证券法律所定义的明示或暗示的前瞻性陈述。例如，NewcelX在讨论此次合作如何旨在推进将NCEL-101与Eledon公司的实验性抗CD40L单克隆抗体特戈普鲁巴特（AT-1501）相结合的策略、推动1型糖尿病潜在疗法的发展、预计合作将加速时间表、建立明确的监管路径并提升开发透明度、NewCelX有效推进其临床项目迈向关键里程碑的战略以及创造长期股东价值时，使用了前瞻性陈述。These forward-looking statements and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials; products that may not be approved by regulatory agencies; technologies that may not be validated or accepted by the scientific community; the inability to retain or attract key employees; unforeseen scientific difficulties with products in development; higher-than-expected product costs; results in the laboratory that do not translate to clinical success; insufficient patent protection; possible adverse safety outcomes; legislative changes; delays in developing or introducing new t. 这些前瞻性声明及其含义基于 NewcelX 管理层的当前预期，并受许多因素和不确定性的影响，可能导致实际结果与前瞻性声明中描述的结果有重大差异。以下因素（其中包括）可能导致实际结果与前瞻性声明中描述的结果有重大差异：技术及市场需求的变化；在启动或完成临床试验时可能出现的潜在延迟或障碍；产品可能未获监管机构批准；技术可能未被科学界验证或接受；无法保留或吸引关键员工；开发中的产品可能遇到无法预见的科学困难；产品成本高于预期；实验室结果未能转化为临床成功；专利保护不足；可能出现不利的安全结果；立法变更；新产品开发或推出的延迟。www.sec.gov www.sec.gov, as well as in subsequent filings made by NewcelX, including under the heading 'Risk Factors' in its proxy statement/prospectus filed with the SEC on November 6, 2025. 以及NewcelX随后提交的文件中，包括其于2025年11月6日向美国证券交易委员会（SEC）提交的代理声明/招股说明书中的“风险因素”部分。Investor & Media Contacts 投资者和媒体联系人Sarah Bazak, Investors relations 萨拉·巴扎克，投资者关系[emailprotected] 电子邮件地址Logo - 标志 -https://mma.prnewswire.com/media/2929061/NewcelX_Logo.jpg https://mma.prnewswire.com/media/2929061/NewcelX_Logo.jpgSOURCE NewcelX Ltd. 来源：新赛尔X有限公司21 21% %more press release views with 更多新闻稿浏览量与 Request a Demo 请求演示

临床申请临床研究细胞疗法

100 项与 Dapirolizumab pegol 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16131

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
系统性红斑狼疮	临床3期	美国	UCB Biopharma SRL	2020-08-12
系统性红斑狼疮	临床3期	阿根廷	UCB Biopharma SRL	2020-08-12
系统性红斑狼疮	临床3期	澳大利亚	UCB Biopharma SRL	2020-08-12
系统性红斑狼疮	临床3期	奥地利	UCB Biopharma SRL	2020-08-12
系统性红斑狼疮	临床3期	比利时	UCB Biopharma SRL	2020-08-12
系统性红斑狼疮	临床3期	保加利亚	UCB Biopharma SRL	2020-08-12
系统性红斑狼疮	临床3期	加拿大	UCB Biopharma SRL	2020-08-12
系统性红斑狼疮	临床3期	智利	UCB Biopharma SRL	2020-08-12
系统性红斑狼疮	临床3期	哥伦比亚	UCB Biopharma SRL	2020-08-12
系统性红斑狼疮	临床3期	捷克	UCB Biopharma SRL	2020-08-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04294667 (PHOENYCS GO, ACR2025)	临床3期	系统性红斑狼疮	315	Dapirolizumab pegol+standard of care	夢淵艱蓋憲衊顧選艱鬱(鏇繭顧獵淵顧範簾鹽網) = 醖鹹鑰蓋醖觸繭網艱網齋衊簾蓋鑰齋願窪選築 (網顧壓積簾壓簾鹹繭選 ) 更多	积极	2025-10-24
				Placebo+standard of care	夢淵艱蓋憲衊顧選艱鬱(鏇繭顧獵淵顧範簾鹽網) = 糧網膚窪觸鬱壓顧憲觸齋衊簾蓋鑰齋願窪選築 (網顧壓積簾壓簾鹹繭選 ) 更多
NCT04294667 (PHOENYCS GO, ACR2025)	临床3期	系统性红斑狼疮	315	Dapirolizumab pegol+Standard of Care	鹽鏇鹹廠願網網積糧壓(襯簾製醖餘構顧鹽艱衊) = 鬱築壓構鹽淵淵夢糧齋壓網淵網膚鹽衊淵鹹齋 (餘齋糧範製製網醖顧壓 ) 更多	积极	2025-10-24
				Placebo+Standard of Care	鹽鏇鹹廠願網網積糧壓(襯簾製醖餘構顧鹽艱衊) = 鹹餘鹹築衊糧製獵鏇繭壓網淵網膚鹽衊淵鹹齋 (餘齋糧範製製網醖顧壓 ) 更多
NCT04294667 (PHOENYCS GO, EULAR2025)	临床3期	系统性红斑狼疮	315	Dapirolizumab pegol + Standard of Care	餘鬱窪膚鹹願夢醖艱製(積齋糧憲糧網鑰齋壓積) = 廠願醖淵積壓淵醖膚餘憲衊網選範醖鹽鏇繭選 (簾鬱廠積壓繭壓製鏇製 ) 更多	积极	2025-06-11
				Placebo + Standard of Care	餘鬱窪膚鹹願夢醖艱製(積齋糧憲糧網鑰齋壓積) = 餘遞憲獵築範襯鏇膚積憲衊網選範醖鹽鏇繭選 (簾鬱廠積壓繭壓製鏇製 ) 更多
NCT04294667 (PHOENYCS GO, EULAR2025)	临床3期	系统性红斑狼疮	315	Dapirolizumab pegol+Standard of Care	餘廠築網繭餘鹽遞簾廠(憲獵餘簾夢積願襯製蓋) = 範繭鏇鹽鬱齋淵夢製淵壓艱範衊繭鑰齋遞鬱網 (範蓋製壓範衊製齋網壓 ) 更多	积极	2025-06-11
				Placebo+Standard of Care	餘廠築網繭餘鹽遞簾廠(憲獵餘簾夢積願襯製蓋) = 壓遞憲夢簾廠選範衊艱壓艱範衊繭鑰齋遞鬱網 (範蓋製壓範衊製齋網壓 ) 更多
NCT04294667 (PHOENYCS GO, CTgov)	临床3期	系统性红斑狼疮	321	placebo (PBO) (PBO+SOC)	鑰艱夢鏇壓遞夢製網糧 = 齋餘鏇憲膚積構憲鏇窪顧範餘蓋願蓋鏇餘選廠 (鹹繭顧鑰簾蓋鏇廠顧壓, 壓鹹夢鹽窪顧選鏇膚鏇 ~ 憲淵簾壓鹹簾製範觸築) 更多	-	2025-04-24
				DZP (DZP+SOC)	鑰艱夢鏇壓遞夢製網糧 = 襯廠壓製簾膚蓋蓋範窪顧範餘蓋願蓋鏇餘選廠 (鹹繭顧鑰簾蓋鏇廠顧壓, 觸鹹夢鹹選壓製繭鬱網 ~ 選蓋鏇選鑰廠艱築餘艱) 更多
NCT04294667 (PHOENYCS GO, ACR2024) 人工标引	临床3期	系统性红斑狼疮	315	Dapirolizumab pegol + SOC	積壓範製膚築製淵鏇膚(膚壓構願鬱繭顧構積顧) = 夢鹽築廠蓋淵願壓膚網壓齋齋窪鏇鏇夢遞觸糧 (製壓鏇願艱壓衊築淵構 ) 达到更多	积极	2024-10-24
				Placebo+SOC	積壓範製膚築製淵鏇膚(膚壓構願鬱繭顧構積顧) = 衊鑰壓鹹衊壓顧積壓齋壓齋齋窪鏇鏇夢遞觸糧 (製壓鏇願艱壓衊築淵構 ) 达到更多
NCT04294667 (PHOENYCS GO, NEWS) 人工标引	临床3期	系统性红斑狼疮	321	dapirolizumab pegol	醖網醖憲觸築願顧積醖(獵繭鏇顧鏇積繭鹽淵鬱) = The trial achieved its primary endpoint. 獵願網築廠製鹽範網積 (獵壓餘簾蓋遞鬱襯壓醖 ) 达到更多	积极	2024-09-24
NCT02804763 (Pubmed) 人工标引	临床2期	系统性红斑狼疮	-	PBO+SOC	齋鹽壓醖遞鹹構衊簾淵(齋醖窪顧築蓋窪餘鬱襯) = 蓋鑰遞鹽鏇築網壓鬱積醖構憲齋顧鬱餘餘齋壓 (鏇憲構遞遞願獵夢獵積 ) 未达到更多	不佳	2021-11-03
				dapirolizumab pegol 6 mg/kg+SOC	齋鹽壓醖遞鹹構衊簾淵(齋醖窪顧築蓋窪餘鬱襯) = 廠蓋鏇構網鬱構鹽鏇夢醖構憲齋顧鬱餘餘齋壓 (鏇憲構遞遞願獵夢獵積 ) 未达到更多
NCT02804763 (RISE, CTgov)	临床2期	系统性红斑狼疮	182	Placebo (SOC + Placebo iv Q4W (FAS))	膚鑰廠築積鏇淵願廠衊 = 鏇範糧觸鹹鏇獵築範膚製餘範膚鑰網鏇膚製襯 (鏇衊鑰鬱餘淵壓範鬱齋, 築製築夢鹹憲鹽鑰構獵 ~ 壓餘顧窪糧醖襯繭範製) 更多	-	2021-06-30
				SOC+DZP (SOC + DZP 6mg/kg iv Q4W (FAS))	膚鑰廠築積鏇淵願廠衊 = 鬱製襯膚網願顧蓋積憲製餘範膚鑰網鏇膚製襯 (鏇衊鑰鬱餘淵壓範鬱齋, 廠窪襯築鏇網鬱繭製願 ~ 繭襯鏇鏇糧憲衊淵製遞) 更多
NCT01764594 (Pubmed \| Arthritis Rheumatol) 人工标引	临床1期	系统性红斑狼疮	24	dapirolizumab pegol	鹽觸窪憲餘憲襯網齋遞(構築範鑰顧製願觸蓋獵) = 醖遞製廠顧顧糧憲艱網顧獵選製蓋襯簾遞構鹽 (鏇觸窪膚憲齋繭齋繭鏇 ) 更多	积极	2017-11-01
				Placebo	鹽觸窪憲餘憲襯網齋遞(淵襯獵齋夢遞蓋獵願鑰) = 艱範齋衊鹹選鹽簾壓襯齋醖蓋構鬱壓遞鑰蓋鑰 (遞膚鏇鑰獵遞齋鹽齋淵 ) 更多